MV 140 vaccine

Action and Spectrum

Actions and spectrum:

Recent studies have found that sublingual MV140 triggers the production of antibodies and stimulates human dendritic cells to produce T helper (Th) 1, Th17, and interleukin-10. This leads to the generation of anti-inflammatory T-cell responses in secondary lymphoid organs and the bladder. The development of adaptive immunity is believed to be the reason for the observed clinical protection even after treatment is stopped. However, it is possible that trained immunity (activation of innate immune cells leading to increased responsiveness to future bacterial triggers) may also have a role to play.

Drug Interaction

Adverse Reaction

Frequency not defined

• Abdominal discomfort
• Chest infection
• Vaginitis
• Candidiasis
• Nausea
• Fatigue

Black Box Warning

Black Box Warning

No specific black box warning is available

Contraindication / Caution

Contraindication/Caution:

Contraindication:

No contraindications are reported

Pregnancy / Lactation

Pregnancy consideration:

Data about the use of MV 140 in pregnancy is not available

Lactation:

Data about the use of MV 140 in lactation is not available.

Pregnancy categories:

• Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester.
• Category B: There was a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.
• Category C: There was evidence of risk of adverse effects in animal reproduction studies, and there was no adequate evidence in human studies that must take care of potential risks in pregnant women.
• Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
• Category X: Drugs listed in this category outweigh the risks over benefits. Hence, these categories of drugs need to be avoided by pregnant women.
• Category N: There is no data available for the drug under this category

Pharmacology

Pharmacology:

MV 140 vaccine is an oral vaccine containing four different types of whole-cell inactivated bacterial strains of Escherichia coli, Proteus vulgaris, Enterococcus faecalis, and Klebsiella pneumoniae.

Pharmacodynamics:

MV 140 vaccine is administered sublingually. This pathway prevents deterioration from stomach acids and digestive enzymes, resulting in successful transportation.

Pharmacokinetics:

Limited data available

Adminstartion

Administration:

MV 140 vaccine should be administered as two sprays under the tongue (sublingually) once daily for a period of three months.

Patient Information Leaflet

Patient information leaflet

Generic Name: MV 140 vaccine

Why do we use the MV 140 vaccine?

MV 140 vaccine is used to treat rUTI (recurrent urinary tract infections). It is a sublingual vaccine consisting of four different inactivated whole-cell bacterial strains of E.coli, K.pneumoniae, E.faecalis, and P.vulgaris.